Core Insights - Axogen, Inc. announced positive topline results from its REPOSE clinical study, demonstrating that Axoguard Nerve Cap is statistically superior to standard-of-care neurectomy in reducing total pain for symptomatic neuroma patients over a 12-month follow-up period [1][2] - The study met its primary endpoint for non-inferiority in pain reduction as measured by the visual analog scale, with a p-value of less than 0.05 [1][3] Company Overview - Axogen is a leader in developing and marketing surgical solutions for peripheral nerve injuries, focusing on technologies that enhance nerve regeneration and repair [5] - The company offers a comprehensive portfolio of products for both scheduled and emergent trauma procedures, addressing various conditions caused by nerve defects or injuries [6][7][8] Product Details - Axoguard Nerve Cap is a proprietary surgical implant made from porcine submucosal extracellular matrix, designed to protect peripheral nerve ends and reduce the development of symptomatic neuromas [4][8] - The product is part of a broader range of offerings that includes Avance® nerve graft and Axoguard Nerve Connector®, aimed at improving outcomes for patients with peripheral nerve damage [8]

AxoGen, Inc. (NASDAQ:AXGN) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Adanna Alexander - IR Consultant Karen Zaderej - Chairman, CEO and President Pete Mariani - EVP and CFO Conference Call Participants Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Dave Turkaly - JMP Securities Operator Greetings. Welcome to the AxoGen Reports Third Quarter 2023 Financial Results. At this time, all participants are in a listen-only mode. A question-and-answer session w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to______________ Commission file number: 001-36046 Axogen, Inc. ...

Corporate presentation August 7, 2023 nasdaq: axgn Safe harbor statement This presentation contains “forward-looking” statements as related to the continued impact of COVID-19, global supply defined in the Private Securities Litigation Reform Act of 1995. chain issues, record inflation, hospital staffing issues, product These statements are based on management's current development, product potential, expected clinical enrollment expectations or predictions of future conditions, events, or timing and outcom ...

AxoGen, Inc. (NASDAQ:AXGN) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Adanna Alexander - Investor Relations Consultant Karen Zaderej - Chairman, Chief Executive Officer and President Pete Mariani - Executive Vice President and Chief Financial Officer Conference Call Participants Michael Sarcone - Jefferies Dave Turkaly - JMP Securities Ross Osborn - Cantor Fitzgerald Caitlin Cronin - Canaccord Genuity Chris Pasquale - Nephron Research Operator Greetings. Welcome to the A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to______________ Commission file number: 001-36046 Axogen, Inc. (Exa ...

Corporate presentation May 9, 2023 nasdaq: axgn Safe harbor statement This presentation contains “forward-looking” statements as of COVID-19, global supply chain issues, record inflation, defined in the Private Securities Litigation Reform Act of 1995. hospital staffing issues, product development, product These statements are based on management's current potential, expected clinical enrollment timing and outcomes, expectations or predictions of future conditions, events, or regulatory process and approval ...

AxoGen, Inc. (NASDAQ:AXGN) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ET Company Participants Ed Joyce – Director-Investor Relations Karen Zaderej – Chairman, Chief Executive Officer and President Pete Mariani – Executive Vice President and Chief Financial Officer Conference Call Participants Chris Pasquale – Nephron Mike Sarcone – Jefferies Ryan Zimmerman – BTIG Kyle Rose – Canaccord David Turkaly – JMP Securities Operator Good day ladies and gentlemen. And welcome to the AxoGen Incorporated Rep ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to______________ Commission file number: 001-36046 Axogen, Inc. (Ex ...

AxoGen, Inc. (NASDAQ:AXGN) Q4 2022 Earnings Conference Call March 14, 2023 8:00 AM ET Company Participants Ed Joyce - Director, IR Karen Zaderej - Chairman, CEO & President Pete Mariani - EVP & CFO Conference Call Participants Mike Sarcone - Jefferies Chris Pasquale - Nephron Kyle Rose - Canaccord Genuity Ryan Zimmerman - BTIG Ross Osborn - Cantor Fitzgerald Dave Turkaly - JMP Securities Operator Welcome to the AxoGen Fourth Quarter 2022 Conference Call. [Operator Instructions] As a reminder, this conferenc ...